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OBJECTIVES: The risk of blindness from glaucoma can be reduced by early detec-
tion and treatment. A domestic large-scale surveillance (Tajimi Study) shows that 
approximately 90% of glaucoma patients of 40 years or older are undiagnosed, and 
initiation of the treatment is delayed. In this study the glaucoma treatment was 
investigated to understand the real-world situation of glaucoma therapy using claim 
data in Japan. METHODS: This was a retrospective cohort study. The data were 
extracted from a Japanese healthcare database (MinaCare Co., Ltd), which contained 
claim data obtained from approximately 2.0 million members of employment-based 
health insurance groups and their dependents. The ICD-10 classification was used 
to identify glaucoma patients. A washout period of 6 months before enrollment was 
set during which there were no records of prescriptions of antiglaucoma drugs or 
glaucoma surgery. Antiglaucoma ophthalmic solutions or surgery for initial treat-
ment, persistence and change in medication were investigated. RESULTS: Out of 
2,074,499 people in the database as of August 2014, we identified 42,470 glaucoma 
patients and the target group who met the wash-out conditions involved 6,333 
patients (male: 3,618; female: 2,715). About 75% of the patients were between 40 to 
69 years old and about 10% were 70 years or older. Regarding the initial treatment, 
most patients started with topical antiglaucoma treatment and only 24 patients 
underwent surgery. The first prescription of antiglaucoma drug included 1 agent 
in 87%, and cases with 2 agents (10%), 3 agents (3%), or more than 3 agents (0.3%) 
were also identified. The most prescribed one was latanoprost (26%) followed by 
tafluprost (17%), and carteolol (10%). CONCLUSIONS: In this study, the initial treat-
ment in most of the patients followed the treatment guidelines. However, lack of 
disease awareness among potential patients and accessibility to early screening and 
diagnosis of glaucoma may exist, and it should be given sufficient consideration.
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OBJECTIVES: Psoriasis (PSO) and psoriatic arthritis (PsA) are immune-mediated 
systemic inflammatory diseases; adalimumab (ADA) and etanercept (ETN) are 
among the most commonly used first-line biologic agents. As per FDA-approved 
dosage and administration, newly initiated PSO patients receive a higher loading 
dose followed by a regular maintenance dose. In clinical practice, however, patients 
may receive higher than recommended (increased) doses even during the mainte-
nance phase of treatment. Given linear pricing of these medications, our objective 
was to determine if the increased dosing schedule increases payer costs and to 
what degree. METHODS: Continuously enrolled adult patients with ≥ 2 outpa-
tient diagnoses of PSO (ICD-9 code: 696.1) or PsA (ICD-9 code: 696.0) were selected 
from the Symphony PTD Claims Database if their first biologic prescription date 
(index date) fell between May 2010 and April 2013. Patients were required to be 
treatment-naïve only to ADA or ETN pre-index. The cost analysis took place over 
12 months post-index. Regular (increased) maintenance dosing was defined as 
ADA 40 mg (> 40 mg) biweekly starting 1 week post-index and ETN 50 mg (> 50 mg) 
weekly starting 3 months post-index. Costs were imputed based on 2015 wholesale 
acquisition costs: $36.4/mg of ADA and $14.9/mg of ETN. RESULTS: 15.0% of 21,234 
ADA patients received increased maintenance doses for PSO and 18.0% of 8,908 for 
PsA. For ETN, the proportion was 31.9% of 16,318 for PSO and 17.0% of 7,647 for PsA. 
Average annual costs for patients receiving an increased vs. regular dose of ADA 
were: PSO: $40,042 vs. $27,319 (P< 0.001), PSA: $43,949 vs. $26,570 (P< 0.001). Average 
annual costs for patients receiving an increased vs. regular dose of ETN were: PSO: 
$46,148 vs. $30,289 (P< 0.001), PSA: $43,816 vs. $30,653 (P< 0.001). CONCLUSIONS: 
A large proportion of patients treated with commonly used biologic agents are 
maintained on increased maintenance doses, significantly increasing payer 
costs.
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OBJECTIVES: Fluoroquinolones are broad-spectrum antibiotics commonly used in 
the treatment of respiratory tract infections, uncomplicated urinary tract infec-
tions and gastrointestinal infections. This study described and analyzes trends in 
the utilization, spending, and average per-prescription cost of fluoroquinolones 
individually and overall, by the Medicaid programs from 1991 to 2013. METHODS: 
A retrospective, descriptive analysis was performed using the publicly available 
national Summary Files from the Medicaid State Drug Utilization Data maintained 
by the Centers for Medicare & Medicaid Service. Study drugs included ciprofloxa-
cin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, and ofloxacin, as well as 
recently withdrawn drugs, grepafloxacin (1999), sparfloxacin (2001), trovafloxacin 
(2001), and gatifloxacin (2006). Annual prescription counts and reimbursement 
amounts were calculated for all fluoroquinolones reimbursed by Medicaid. Average 
per-prescription spending as a proxy for drug price was calculated (estimated) for 
all generic and brand drugs by dividing reimbursement by the number of prescrip-
tion. RESULTS: The total number of fluoroquinolone prescriptions rose 340% from 
1.66 million in1991 to 5.65 million in 2005, and then decreased to 4.21 million in 
2013. Total expenditures on fluoroquinolones increased from $81 million in 1991 to 
$395 million in 2004, and then decreased to $163 million in 2013. The average pre-
prescription price for generic ciprofloxacin was $7.76 in 2013, whereas the price 
OBJECTIVES: Patient-reported outcome (PRO) measures provide patients and clini-
cians with a tool to assess physical, social, and psychological functioning. Individual 
and aggregated data can inform treatment decision making and aid patient 
management. Existing PRO measures for psoriasis typically do not fully capture 
either impact on emotional wellbeing or coping behaviors, including modifiable 
behaviors associated with poor health outcomes and comorbid disease. The aim 
of this study was to develop content for a new PRO for the clinical management of 
psoriasis. METHODS: Patients with chronic plaque psoriasis were identified and 
recruited through two psoriasis-specific clinics. Content was developed and itera-
tively refined through: a) in-depth qualitative, face-to-face interviews (n= 30) using 
a semi-structured interview guide and analyzed using NVivo; b) development of a 
conceptual model and draft items with an expert panel; and c) cognitive debriefing 
of draft items, response scale, and recall period to determine understanding and 
relevance to patients (n= 8). RESULTS: Qualitative analysis revealed seven main 
domains of concern to patients with psoriasis including symptoms and impact on 
negative wellbeing, positive wellbeing, daily activities, illness beliefs, treatment 
beliefs, and coping techniques. A conceptual model is presented, postulating rela-
tionships between concepts identified by patients. An initial bank of 97 items was 
developed; cognitive debriefing revealed that most items were deemed relevant to 
psoriasis experience and could be accurately recalled over a 14-day time period. Six 
items were deleted through redundancy, lack of relevance, or poor understanding. 
A 91-item bank across six sub-scales remained. CONCLUSIONS: The new measure, 
PROMPT, was derived from patient-reported experience and demonstrates initial 
face and content validity in a plaque psoriasis patient population. Further confir-
mation and refinement of items, scales, and scoring structure is planned through 
a large-scale quantitative study using Rasch techniques.
PSS36
Client ACCePtAnCe triAl witH inJeCtAble CefoveCin SoDiUm in DogS 
AS A firSt line of treAtment for SUPerfiCiAl PyoDermA, woUnDS, 
AnD AbSCeSSeS CAUSeD by SUSCePtible StrAinS of StAPHloCoCCUS 
intermeDiUS AnD StrePtoCoCCUS CAniS groUP g
Wright A.K.1, Russo S.2, DiFranco B.2, Gasper S.2, Amodie D.2
1Zoetis, Greeley, CO, USA, 2Zoetis, Florham Park, NJ, USA
OBJECTIVES: Many veterinarians are hesitant to recommend cefovecin sodium for 
subcutaneous administration as a first treatment for superficial pyoderma in dogs 
because there is a perception that dog owners will not accept the cost compared to 
less expensive oral medications requiring repeated administration. The objective 
was to assess the impact of weight of the dog using a margin markup pricing method 
on the acceptance by dog owners of cefovecin sodium as a first line treatment 
in appropriate cases. METHODS: Thirty veterinarians in 22 different geographical 
veterinary practices that were members of CAPNA a group of veterinary hospitals 
owned by veterinarians in the US were asked to offer cefovecin sodium as a first 
line treatment for appropriate cases. The date of examination, weight of the dog 
and owner’s acceptance or decline was recorded for a two month period. Owners 
were charged using the weight of the dog multiplied by 1.25 plus a $45 margin 
markup. RESULTS: Of the sample of 683 dogs, 76.28% (n= 521) accepted cefovecin 
sodium as a single subcutaneous administration with an average weight of 32.57 
lbs. and a range of 3-135 lbs. 23.7% (n= 162) declined treatment with an average 
weight of 58.44 lbs. with a range of 10.20-155 lbs. The difference in weights of 25.87 
lbs. was statistically significant (P< 0.0001). The average cost of the accepted cefo-
vecin sodium injection for 32.57 lb dog is $85.71. The average cost of the declined 
cefovecin sodium injection is $118.05.The average cost of the alternative oral medi-
cations for cefpodoxime proxetil administered once daily is $29.96 and cephalexin 
administered twice daily is $5.04. CONCLUSIONS: The dog owners in this study 
accepted treatment with cefovecin sodium as a first line of therapy in 76.2% of the 
cases even though the cost of the onetime treatment was 3 to17 times more than 
oral alternatives.
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OBJECTIVES: To investigate the availability and affordability of antiglaucoma 
medicines in Benin City, Nigeria. METHODS: The study employed retrospective 
and prospective cross sectional design, using data collection forms, WHO/HAI 
data collection format for collection and analysis of medicine prices in public 
and private sectors. The name of the antiglaucoma drugs (branded and generic), 
usual quantities, price prescribed for a month supply to patients, strength, unit 
pack, brand name, lowest priced generic (LPG) were recorded. Physical sighting of 
product was done to confirm availability in that facility. Data was analyzed with 
WakAfford1.0. Medicine Affordability Calculator developed for this study based 
on USD103 (NGN17, 000) minimum wage per month for the least paid government 
worker RESULTS: Thirty-six antiglaucoma medicines were surveyed in the three 
main sectors. The branded products in private pharmacies had 47.22% availabil-
ity, private clinics 38% and public hospital 25%, while the generic medicines had 
25% in private pharmacy, 22.22% in clinics and 19.44% in public hospitals. The 
most affordable branded product in Private pharmacies was acetazolamide tab-
lets (0.16 ± 0.02 days) and Timolol 0.5% eye drop (0.59 ± 0.04 days), while the most 
unaffordable product is Combigan® (brimonidine + timolol) (12.71 ± 0.17days). 
However timolol 0.25% was the most affordable in private clinic while Xalacomb® 
(latanoprost + timolol) was the most unaffordable CONCLUSIONS: The availability 
of antiglaucoma drugs in Benin City is suboptimal and some are unaffordable 
across the different sectors. Government and donor agencies should subsidize 
and make them accessible to patients. Acknowledgement: WakAfford 1.0 afford-
ability calculator developed with BaseCase Interactive donated in an academic 
partnership by BaseCase (Berlin, Germany). Available at www.pub.basecase.com/ 
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